General Practice Research Database Seroquel XR Safety Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

37372 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e. the comparison group) and to quantify the risk of developing newly diagnosed outcomes of interest in new users of quetiapine XR as well as in other study drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy

NCT01128114

Acute Bipolar Mania

TERMINATED PHASE4

PHARMO Institute Seroquel Safety Study

NCT01342120

Schizophrenia Major Depressive Disorder Bipolar Disorder +1 more

COMPLETED

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

NCT00422214

Affective Psychosis, Bipolar Depression, Bipolar Manic-Depressive Psychosis +1 more

COMPLETED PHASE3

Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

NCT00926393

Bipolar Depression

COMPLETED PHASE4

Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study

NCT01689389

Schizophrenia Bipolar Episodes

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epidemiology study to assess the safety of a new slow-release form of Seroquel (quetiapine) in the post-marketing phase in the UK.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Major Depressive Disorder Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Quetiapine XR group

No interventions assigned to this group

Non-quetiapine comparison group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Episodes of new use (\>/=1 prescription) of quetiapine XR or other study drugs

Exclusion Criteria

* Less than two years of recorded history before the start of the marketing of quetiapine XR (or cohort entry date)
* If the duration and dose of the antipsychotic drug cannot be determined

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No